← Back to Search

PI3K Inhibitor

Parsaclisib + Ruxolitinib for Myelofibrosis

Phase 3
Waitlist Available
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Palpable spleen of ≥ 5 cm below the left costal margin on physical examination at the screening visit
Active symptoms of MF at the screening visit, as demonstrated by the presence of a TSS of ≥ 10 using the Screening Symptom Form
Must not have
History of Grade 3 or 4 irAEs from prior immunotherapy
Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 749 days
Awards & highlights
Pivotal Trial

Summary

This trial will compare the effectiveness of a new drug, parsaclisib, to a placebo when used with another drug, ruxolitinib, to treat myelofibrosis.

Who is the study for?
This trial is for adults with myelofibrosis, a type of bone marrow cancer. They should have an intermediate to high risk level, be able to perform daily activities (ECOG score 0-2), and have a life expectancy over 24 weeks. Participants need a spleen that's enlarged by at least 5 cm and must not plan on becoming pregnant or fathering children.
What is being tested?
The study tests the effectiveness of combining parsaclisib with ruxolitinib versus using ruxolitinib with a placebo in treating myelofibrosis. The goal is to see if adding parsaclisib improves patient outcomes compared to just using ruxolitinib alone.
What are the potential side effects?
Possible side effects include digestive issues, liver problems, infections due to weakened immune system, blood disorders like anemia or thrombocytopenia (low platelet count), fatigue, and potential allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My spleen is enlarged and can be felt at least 5 cm below my ribcage.
Select...
I have active symptoms of myelofibrosis with a symptom score of 10 or more.
Select...
I have or am willing to get a bone marrow biopsy for my myelofibrosis diagnosis.
Select...
I can take care of myself and am up and about more than half of my waking hours.
Select...
My condition is classified as intermediate-1, intermediate-2, or high risk.
Select...
I have been diagnosed with a form of myelofibrosis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had severe side effects from previous immunotherapy.
Select...
I cannot swallow pills due to a condition in my upper digestive system.
Select...
I haven't taken strong CYP3A4 affecting drugs recently or won't during the study.
Select...
My liver and kidney functions are not normal.
Select...
I am currently being treated for an infection.
Select...
I have not received a live vaccine in the last 30 days.
Select...
I am HIV positive.
Select...
I have not taken drugs like INCB040093 or idelalisib for my condition.
Select...
I have hepatitis B or C that needs treatment.
Select...
I have had an active cancer within the last 2 years.
Select...
I have previously used a JAK inhibitor medication.
Select...
I am not taking any medications that are not allowed in the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 749 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 749 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of Participants Achieving ≥35% Reduction in Spleen Volume From Baseline to Week 24 as Measured by Magnetic Resonance Imaging [MRI] (or Computed Tomography [CT] Scan in Applicable Participants)
Secondary study objectives
Change in TSS From Baseline to Week 24 as Measured by the MFSAF v4.0 Diary
Duration of Maintenance of a ≥35% Reduction in Spleen Volume
Number of Participants With Any Grade 3 or Higher TEAE
+5 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Group A : parsaclisib + ruxolitinibExperimental Treatment2 Interventions
Participants will receive parsaclisib and ruxolitinib starting from Day 1 for the duration of study, ruxolitinib dose will be determined by baseline platelet count.
Group II: Group B : placebo + ruxolitinibPlacebo Group2 Interventions
Participants will receive placebo and ruxolitinib starting from Day 1 for the duration of study, ruxolitinib dose will be determined by baseline platelet count.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
parsaclisib
2021
Completed Phase 2
~120
ruxolitinib
2017
Completed Phase 3
~660

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor
391 Previous Clinical Trials
63,559 Total Patients Enrolled
Albert Assad, M.DStudy DirectorIncyte Corporation

Media Library

Parsaclisib (PI3K Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04551066 — Phase 3
Myelofibrosis Research Study Groups: Group B : placebo + ruxolitinib, Group A : parsaclisib + ruxolitinib
Myelofibrosis Clinical Trial 2023: Parsaclisib Highlights & Side Effects. Trial Name: NCT04551066 — Phase 3
Parsaclisib (PI3K Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04551066 — Phase 3
~57 spots leftby Nov 2025